PCSK9 and metabolic syndrome: Yet, in recent years, several innovative drug treatments have become available to clinicians, especially with regard to dyslipidemia, such as bempedoic acid, human monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9), and inclisiran, allowing for multiple combined LLTs to reach an LDL-C reduction of even more than 80% compared to that of the baseline [10,11].